Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Phase III Trials
88%
Hyperthermia
88%
Breast Cancer
88%
Recurrent Disease
88%
Immunoglobulin E
88%
Immunoglobulin E Antibody
88%
Folate Receptor 1
88%
Erethism
88%
Ovary Carcinoma
50%
Ovary Cancer
38%
Immunoglobulin E Receptor
38%
Overall Survival
33%
Disease Free Survival
33%
Survival Time
33%
Normal Human
25%
Mast Cell Leukemia
12%
Chimeric Antibody
12%
Recombinant Antigen
12%
Ovary Tumor
12%
Epitope
12%
Solid Malignant Neoplasm
12%
Immunoglobulin G1
12%
Preclinical Study
12%
Malignant Neoplasm
12%
Dosimetry
11%
Breast Carcinoma
11%
Medicine and Dentistry
Hyperthermia
88%
Recurrent Disease
88%
Breast Cancer
88%
Sex Worker
88%
Phase III Trials
88%
Disease Free Survival
33%
Survival Time
33%
Overall Survival
33%
Qualitative Design
29%
Public Health
29%
Clinical Health
29%
Horizontal Disease Transmission
29%
Human Immunodeficiency Virus
29%
Early Diagnosis
29%
Men Who Have Sex with Men
29%
Distress Syndrome
29%
Diseases
29%
Radiation Therapy
22%
Neoplasm
11%
Dosimetry
11%
Arm
11%
Breast Carcinoma
11%
Immunology and Microbiology
Immunoglobulin E Antibody
88%
Immunoglobulin E
88%
Type I Hypersensitivity
88%
Basophil Activation
88%
Basophil
44%
Fc Receptor
22%
CD63
22%
Degranulation
22%
Normal Human
22%
Cross Linking
22%
Effector Cell
22%
Recombinant Antigen
11%
Mast Cell
11%
Basophilic Leukemia Cell Line
11%
Immunoglobulin G1
11%
Mediator
11%
Xenograft
11%
Macrophage
11%
Eosinophil
11%
Chimeric Antibody
11%
Epitope
11%
Folic Acid Blood Level
11%
Tumor Cell
11%
Preclinical Study
11%